KR20170019457A - 땅콩 알레르기의 치료를 위한 핵산 - Google Patents

땅콩 알레르기의 치료를 위한 핵산 Download PDF

Info

Publication number
KR20170019457A
KR20170019457A KR1020177001547A KR20177001547A KR20170019457A KR 20170019457 A KR20170019457 A KR 20170019457A KR 1020177001547 A KR1020177001547 A KR 1020177001547A KR 20177001547 A KR20177001547 A KR 20177001547A KR 20170019457 A KR20170019457 A KR 20170019457A
Authority
KR
South Korea
Prior art keywords
ser
leu
arg
glu
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177001547A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 헤알
테리 헤이랜드
Original Assignee
이뮤노믹 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노믹 쎄라퓨틱스, 인크. filed Critical 이뮤노믹 쎄라퓨틱스, 인크.
Publication of KR20170019457A publication Critical patent/KR20170019457A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177001547A 2014-06-23 2015-06-23 땅콩 알레르기의 치료를 위한 핵산 Withdrawn KR20170019457A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015981P 2014-06-23 2014-06-23
US62/015,981 2014-06-23
PCT/US2015/037240 WO2015200357A2 (en) 2014-06-23 2015-06-23 Nucleic acids for treatment of peanut allergies

Publications (1)

Publication Number Publication Date
KR20170019457A true KR20170019457A (ko) 2017-02-21

Family

ID=53546722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001547A Withdrawn KR20170019457A (ko) 2014-06-23 2015-06-23 땅콩 알레르기의 치료를 위한 핵산

Country Status (9)

Country Link
US (2) US20170304432A1 (cg-RX-API-DMAC10.html)
EP (1) EP3157558A2 (cg-RX-API-DMAC10.html)
JP (1) JP2017521064A (cg-RX-API-DMAC10.html)
KR (1) KR20170019457A (cg-RX-API-DMAC10.html)
CN (1) CN106459994A (cg-RX-API-DMAC10.html)
AU (2) AU2015280143A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016030439A2 (cg-RX-API-DMAC10.html)
CA (1) CA2952726A1 (cg-RX-API-DMAC10.html)
WO (1) WO2015200357A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210142000A (ko) * 2019-03-13 2021-11-23 소마젠 인크 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제
KR20220063460A (ko) * 2020-11-10 2022-05-17 (주)프로테옴텍 밀가루 유래의 오메가-5-글리아딘의 신규 에피토프 중합체 및 이의 용도

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2017186808A1 (en) * 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
CA3099505A1 (en) 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
WO2019216394A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
CN109115737B (zh) * 2018-07-27 2021-03-26 青岛大学 一种三螺旋pH生物传感器及其应用
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CN112225815A (zh) * 2020-09-30 2021-01-15 四川携光生物技术有限公司 一种牛奶、小麦、花生及大豆过敏原融合蛋白及其构建方法、应用
CN114438088B (zh) * 2020-11-03 2025-05-23 韩达 一种溶酶体靶向的核酸嵌合体的制备及应用
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN115057927B (zh) * 2022-05-30 2024-02-20 南开大学 一种花生过敏原Ara h1特异性纳米抗体及其应用
WO2025199077A1 (en) * 2024-03-19 2025-09-25 Modernatx, Inc. Tolerizing antigen specific immunotherapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508400A (ja) * 1992-03-03 1995-09-21 ザ ソーク インスティチュート フォア バイオロジカル スタディーズ 受容体のインターナライゼーション・シグナル
AU2003256240A1 (en) * 2002-08-29 2004-03-19 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
US9774230B2 (en) * 2015-11-25 2017-09-26 Caterpillar Inc. Generator set having coupling member between flywheel and generator

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210142000A (ko) * 2019-03-13 2021-11-23 소마젠 인크 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제
KR20220063460A (ko) * 2020-11-10 2022-05-17 (주)프로테옴텍 밀가루 유래의 오메가-5-글리아딘의 신규 에피토프 중합체 및 이의 용도

Also Published As

Publication number Publication date
US20170304432A1 (en) 2017-10-26
WO2015200357A3 (en) 2016-04-21
WO2015200357A2 (en) 2015-12-30
EP3157558A2 (en) 2017-04-26
CN106459994A (zh) 2017-02-22
JP2017521064A (ja) 2017-08-03
CA2952726A1 (en) 2015-12-30
AU2020204277A1 (en) 2020-07-16
BR112016030439A2 (pt) 2018-07-17
US20190298821A1 (en) 2019-10-03
AU2015280143A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
US20190298821A1 (en) Nucleic Acids for Treatment of Peanut Allergies
EP2861240B1 (en) Nucleic acids for treatment of allergies
US7446185B2 (en) Her2/neu target antigen and use of same to stimulate an immune response
US20040258688A1 (en) Enhanced antigen delivery and modulation of the immune response therefrom
US20040242481A1 (en) Use of hmgb1 for the activation of dendritic cells
JP2001503741A (ja) アレルギー性肺疾患を治療するための方法
KR101195400B1 (ko) 암배아 항원 융합물 및 이의 용도
WO2014187743A1 (en) Gastrin peptide immunogenic composition
US20060251667A1 (en) Recombinant nucleic acid useful for inducing protective immune response against allergens
HK1243732A1 (zh) 编码hnp-1或hnp-2或hnp-3的dna质粒、细菌生产者、镇痛剂(变体)
EP2412811B1 (en) Dna vaccine for alzheimer's disease
JP6353510B2 (ja) アレルギー治療のための核酸
CZ20022192A3 (cs) Konstrukt pro vakcinaci nukleovými kyselinami a vakcina
WO2022251585A9 (en) Dna antibody constructs for use against plasmodium parasites
CN114630675A (zh) 乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
JP6088584B2 (ja) アレルギー治療のための核酸
EA050833B1 (ru) Вакцина против старения
HK40075526A (en) Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
MXPA06009202A (en) Carcinoembryonic antigen fusions proteins and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination